The WHO Operational Handbook on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment provides practical guidance on how to put in place the recommendations at the scale needed to achieve national and global impact. The consolidated guidelines are complemented by this operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB.
The operational handbook provides practical information and tools that complement the recommendations in the guidelines based on best practices and knowledge from the field such as microbiology, clinical and programmatic management. It includes information on different aspects of treatment and care of DR-TB, including multidrug-resistant or rifampicin resistant TB (MDR/RR-TB) and rifampicin susceptible isoniazid resistant TB (Hr-TB). The handbook provides practical guidance on the implementation of the new recommendations on the use of the 6-month BPaLM regimen, and the 9-month all oral regimen and rationale for selection of the most appropriate regimen. In addition, the handbook includes key considerations for design and implementation of the all-oral longer regimens.
This practical guidance includes a consolidated table on weight-based dosing of medicines used in multidrug-resistant TB regimens for adults and children. Besides, there are chapters on adjuncts to DR-TB treatment, the use of antiretrovirals for MDR/RR-TB patients with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment and monitoring treatment response tied to the updated treatment outcome definitions.
- WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
- Handbook Web Annexes
Entire content available on: https://www.who.int/publications-detail-redirect/9789240065116
Language
EnglishTypology
Books/HandbooksTopic
Clinical Management Antimicrobial Resistance (AMR) TuberculosisTarget
Public HealthCountries
USA Canada South America Central America Caribbean Middle East South pacific China India Indochina Singapore Europe & UK Oceania Africa